(B) The BCH- 189 was tested for anti-HIV activity in 1989 and was found to be very
active. (Exh. 2049 at 15).
(C) From October of 1989 to the end of 1990, Dr. Korba worked as a consultalt for
BW, developing and operating an anti-HBV testing program. The Furman inventors discussed
that they "should test compounds in Dr. Korba's anti-HBV screen that exhibit activity against
HfV" because "of similarities in the active sites of the reverse transcriptase enzyme of Hl`V and
the polymerase enzyme of HBV." (Exh. 2049 at tT 4, 6).
(D) Once it was learned that BCH- 189 was active against HIV (in 1989), the Furman
inventors discussed sending BCH- 189 to Dr. Korba for anti-HBV testing since "the compound
could exhibit activity against hepatitis B." (Exh. 2049 at T 7) .6
(E) In autumn of 1989, the Furman inventors had discussions with Dr. Liotta while
attending a virology conference regarding Dr. Liotta's synthesis of nucleoside analogs.
(Exh. 2049 at 18).
(F) The Furman inventors suggested that Dr. Liotta submit any nucleoside analogs he
synthesized to BW for testing for antiviral activity. (Exh. 2049 at ý 8).
(G) Dr. Furman did not mention the possibility of Dr. Korba's anti-HBV test to
Dr. Liotta but did mention BW's "anti-HfV, anti-HSV, and anti-CMV screens". , (Exh. 2049
at 19).
6 We have not been directed to evidence indicating that the sample of BCH- 189
from BioChem Pharma was ever tested for anti-HBV activity.
7 We understand HrV to be human immunodeficiency virus, HSV to be herpes
simplex virus, and CNN to be cytornegalovirus.
12
Page: Previous 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next
Last modified: November 3, 2007